RET and medullary thyroid gland carcinoma: It demonstrates that biomarkers are key for detecting aggressive anaplastic thyroid cancer, prognosticating outcomes for papillary thyroid cancer, and selecting precise treatments for medullary thyroid cancer, especially for cases with RET gene mutations.